ANIP - ANI Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
73.96
+1.46 (+2.01%)
At close: 4:00PM EDT

73.96 0.00 (0.00%)
After hours: 4:53PM EDT

Stock chart is not supported by your current browser
Previous Close72.50
Open73.00
Bid73.93 x 800
Ask75.10 x 900
Day's Range72.41 - 74.82
52 Week Range36.92 - 74.82
Volume197,290
Avg. Volume120,037
Market Cap890.249M
Beta (3Y Monthly)1.79
PE Ratio (TTM)64.43
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire11 hours ago

    ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc.

    BAUDETTE, Minn., June 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that it has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3 million dollars in cash and up to $12.0 million in additional development and commercial milestones. As part of the agreement, ANI will pay a portion of gross profit generated from one of the injectable products to the commercial manufacturing partner. Included in the purchase price, ANI is also acquiring raw materials (API), manufacturing and packaging components, and reference drug valued at approximately $1.5M combined.

  • PR Newswire6 days ago

    ANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference

    BAUDETTE, Minn., June 12, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) will present on June 18, 2019 at Raymond James' Life Sciences and MedTech Conference in New York City. Arthur Przybyl, President and CEO and Stephen Carey, Vice President and CFO, will present at 8:00 AM ET on Tuesday, June 18, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

  • PR Newswirelast month

    ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance

    BAUDETTE, Minn. , May 9, 2019 /PRNewswire/ -- For the first quarter 2019: Net revenues of $52.9 million , an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share ...

  • PR Newswire2 months ago

    ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results

    BAUDETTE, Minn. , May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thursday, May 9, 2019 ...

  • PR Newswire2 months ago

    ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product

    BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced that it has entered into a Distribution Agreement with a U.S. based injectable manufacturer to commercialize a unique specialty injectable product.  Key terms of the 10-year Agreement include cumulative milestones of up to $2M, payable by ANI. Upon launch, ANI will receive a 50% share of net profits generated from product revenues. The product will be commercialized in the ANI label.

  • PR Newswire3 months ago

    ANI Pharmaceuticals Announces Two Generic Product Launches

    BAUDETTE, Minn., March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder ("ADHD"). Also today, ANI announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 400mg/5mL, indicated as a treatment for various infections. After today's announced launches, ANI's generic commercial portfolio now consists of 33 products.

  • PR Newswire4 months ago

    ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance

    BAUDETTE, Minn. , Feb. 27, 2019 /PRNewswire/ -- For the full year ended December 31, 2018 : Record net revenues of $201.6 million , an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted ...

  • PR Newswire4 months ago

    ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results

    BAUDETTE, Minn. , Feb. 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2018 financial results on ...

  • GlobeNewswire4 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Amkor Technology, U.S. Silica, Steven Madden, Rowan Companies, SunOpta, and ANI Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility

    BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced that it has entered an amended and restated five-year Senior Secured Credit Facility (the "Facility") for up to $265.2 million with its existing syndicate of bank lenders (the "Bank Group"). The Facility amends ANI's current $125 million Senior Secured Credit Facility and is structured to provide ANI flexibility in refinancing its 3.00% Convertible Senior Notes due 2019 ("the Convertible Notes"). The principal feature of the Facility is a new $118.0 million Delayed Draw Term Loan available to refinance ANI's Convertible Notes maturing in December 2019.

  • PR Newswire6 months ago

    ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

    BAUDETTE, Minn., Dec. 7, 2018 /PRNewswire/ -- (ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "Notes"). ANI has agreed to repurchase $25.0 million aggregate principal amount of Notes for a total of $26.1 million in cash, including accrued but unpaid interest up to but excluding the closing date for the transactions. In connection with the contemplated repurchase of Notes, ANI has also entered into an agreement with the dealer party to certain convertible note hedge transactions related to the Notes to unwind a corresponding portion of such convertible note hedge transactions.

  • PR Newswire7 months ago

    ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™

    BAUDETTE, Minn., Nov. 15, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period. ANI's President and CEO, Arthur S. Przybyl, said, "I want to thank our employees for their hard work and contributions, which have enabled ANI to be listed on Deloitte's Technology Fast 500™ for the second year in a row.

  • GlobeNewswire7 months ago

    Research Report Identifies Canopy Growth, MSG Networks, ANI Pharmaceuticals, Mistras Group, Rowan Companies, and Chemours with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire7 months ago

    ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

    BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million ...

  • PR Newswire8 months ago

    ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

    BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, ...

  • PR Newswire8 months ago

    ANI Announces Launch of Authorized Generic of Brethine®

    BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market. ANI acquired the NDA for Brethine® (terbutaline sulfate) tablets in December 2016. Arthur S. Przybyl, ANI's President and CEO stated, "ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs.

  • PR Newswire8 months ago

    ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

    BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.  The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. Atacand HCT® is indicated for the treatment of hypertension.

  • PR Newswire9 months ago

    ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/cantor7/anip/ and will be archived and available through the link through January 1, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

  • PR Newswire10 months ago

    ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

    Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

  • ACCESSWIRE10 months ago

    ANI Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 10:30 AM Eastern ...

  • PR Newswire10 months ago

    ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance

    Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipeline Re-commercialization Efforts Targets sNDA Filing for Cortrophin Gel by ...

  • PR Newswire10 months ago

    ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference

    BAUDETTE, Minn., Aug. 6, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) announced today that it will present on Thursday, August 9, 2018 at 2:30 PM ET at the Canaccord Genuity 38th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

  • PR Newswire11 months ago

    ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results

    BAUDETTE, Minn. , Aug. 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, ...